All Updates

All Updates

icon
Filter
Funding
Nido Bio raises USD 109 million in Series A, Series B, and seed funding
Precision Medicine
May 15, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 15, 2023

Nido Bio raises USD 109 million in Series A, Series B, and seed funding

Funding

  • Clinical-stage drug development company Nido Biosciences (Nido Bio) raised a total of  USD 109 million in seed, Series A, and Series B funding rounds. The Series A round was co-led by 5AM Ventures, Abingworth, and Bessemer Venture Partners, with participation from Osage University Partners and Eli Lilly and Company. Bioluminescence Ventures led the Series B round with participation from additional new investors. 

  • The funds will be used to expedite its lead program, NIDO-361, into clinical trials and build out its pipeline of new programs. The company is also planning to increase its team of drug developers and scientists.

  • Founded through the 4:59 Initiative at 5AM Ventures, Nido Bio is developing small-molecule precision medicines for debilitating neurological diseases, leveraging advancements in human genetics and disease understanding. Nido Bio’s lead candidate, NIDO-361, is being developed for the treatment of patients with spinal and bulbar muscular atrophy. It also has additional programs addressing neurodegenerative and peripheral inflammatory diseases, utilizing a functional genomics discovery platform based on human cell lines.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.